Tempus stock tumbles after short seller questions revenue sources

Tempus AI (TEM) shares fell 19% on May 28th following a short seller report from Spruce Point Capital Management alleging potential financial reporting issues and inflated AI revenue claims, specifically questioning a SoftBank joint venture and AstraZeneca partnership; the report suggests a 50-60% downside risk. Stifel analyst Dan Arias countered, stating that while some aspects of Tempus's business warrant scrutiny, he does not believe there is fraud, while Tempus dismissed the report as inaccurate and reaffirmed its commitment to shareholder value and AI-driven healthcare advancements.

Analysis

Tempus AI's stock experienced a significant downturn, falling 19% to $53.20 on May 28, following a report from short-seller Spruce Point Capital Management that posited a potential 50% to 60% downside risk. The report cast doubt on Tempus AI's artificial intelligence capabilities, alleging that AI applications generated only $12.4 million, or 2% of total revenues, in 2024, and raised concerns about "aggressive accounting, financial reporting and suspicious revenue-generating partnerships." Specifically, Spruce Point highlighted a 2024 joint venture with SoftBank, where each contributed $95 million, suggesting potential "round-tripping capital to create revenue and income for Tempus." The report also scrutinized Tempus's partnership with AstraZeneca and PathosAI, labeling the $200 million data licensing and model development deal as embodying "extreme financial engineering" and raising "profound conflict-of-interest concerns." Tempus AI, which went public in June 2024, dismissed the report as "riddled with hypotheticals and inaccuracies," reaffirming its focus on strong financial performance and AI in healthcare, and subsequently issued a press release touting 10 years of operations and nearly 1,500 research projects. Stifel analyst Dan Arias acknowledged that while certain aspects of Tempus's business warrant scrutiny, particularly the complexity of the AstraZeneca/PathosAI deal and the substantiation of its AI claims, he does not suspect fraud, opining that questioning is reasonable for an early-stage public company. Despite a slight recovery to $54.43 on May 29, the stock remained down 14% from its May 28 opening price of $63.99, reflecting persistent investor concern underscored by a moderately negative general sentiment (-0.55) and a very negative ticker-specific sentiment for TEM (-0.8).

Key Decisions for Investors

• Investors should anticipate continued share price volatility for Tempus AI and exercise caution due to the serious allegations raised by Spruce Point Capital Management, despite the company's rebuttal.
• A thorough review of Tempus AI's upcoming financial disclosures is crucial, focusing on revenue recognition practices, detailed breakdowns of AI-derived revenue, and the economic substance and accounting treatment of its joint ventures and partnerships, particularly with SoftBank and AstraZeneca/PathosAI.
• Monitor for further independent analysis or regulatory inquiries into the allegations, as substantiation or refutation of Spruce Point's claims will be critical in assessing the company's fair value and credibility, especially concerning its AI positioning and financial reporting integrity.